Jennison Associates LLC reduced its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 7.5% in the fourth quarter, Holdings Channel reports. The firm owned 3,275,922 shares of the company’s stock after selling 266,287 shares during the period. Jennison Associates LLC’s holdings in Apellis Pharmaceuticals were worth $196,097,000 at the end of […]
Jennison Associates LLC lessened its holdings in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 7.5% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 3,275,922 shares of the company’s stock after selling 266,287 shares during the period. Jennison Associates LLC owned 2.76% of Apellis Pharmaceuticals […]
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective decreased by Wedbush from $67.00 to $57.00 in a report issued on Wednesday morning, Benzinga reports. Wedbush currently has a neutral rating on the stock. Wedbush also issued estimates for Apellis Pharmaceuticals’ Q1 2024 earnings at ($0.83) EPS, Q4 2024 earnings at ($0.27) EPS, FY2024 […]
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Get Free Report)’s share price fell 3.3% during mid-day trading on Monday . The stock traded as low as $54.07 and last traded at $54.07. 120,819 shares were traded during trading, a decline of 92% from the average session volume of 1,495,266 shares. The stock had previously closed at $55.91. […]
Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report)‘s stock had its “outperform” rating reiterated by Robert W. Baird in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $81.00 price target on the stock. Robert W. Baird’s target price points to a potential upside of 21.68% from the stock’s previous close. […]